Physician profile
David Gavin Dillard
NPI 1558327072
$9,273.29
in general payments reported to CMS, 2019-2025
29 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 80% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,849 · 2020: $577 · 2021: $821 · 2022: $902 · 2023: $281 · 2024: $2,390 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Travel and Lodging: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.02 |
| Travel and Lodging | $835.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $4,271.79 | 2019-2025 | |
| Intersect Ent, INC. | $698.41 | 2019-2022 | |
| Optinose US, INC. | $671.26 | 2019-2025 | |
| Acclarent, INC | $607.96 | 2019-2024 | Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $497.04 | 2021-2025 | Dupixent |
| Inspire Medical Systems, INC. | $440.40 | 2024-2025 | Inspire |
| Stryker Corporation | $322.69 | 2019-2023 | Xpress Ent Dilation System, Audion Et Dilation System |
| Spirair, INC. | $291.00 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $271.41 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $199.05 | 2021-2025 | Nucala |
| Genzyme Corporation | $167.16 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $111.61 | 2021 | |
| Integra Lifesciences Corporation | $106.96 | 2020-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Xeris Pharmaceuticals, INC. | $106.63 | 2021 | |
| Hikma Pharmaceuticals USA | $99.27 | 2022-2025 | Ryaltris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.85 | 2019 | |
| Kaleo, INC. | $92.25 | 2021-2024 | Auvi-Q |
| Neurent Medical Limited | $46.42 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Pacira Pharmaceuticals Incorporated | $20.99 | 2021 | |
| Amgen INC. | $20.70 | 2025 | |
| Smith+Nephew, INC. | $16.71 | 2019 | |
| Merck Sharp & Dohme LLC | $16.65 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.42 | 2025 | Xhance |
| Medtronic, INC. | $15.88 | 2024 | Sinuva |
| Astrazeneca Pharmaceuticals LP | $15.06 | 2025 | Tezspire |
| Alk-Abello, INC | $14.96 | 2022 | |
| Baxter Healthcare | $14.56 | 2022 | |
| Watermark Medical, INC. | $14.25 | 2021 | |
| Olympus America INC. | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.